CNS Spectrums
Journal Impact IF - Analysis · Trend · Prediction · Ranking


New

Journal Impact IF

2019-2020

3.356

-14.8 %

Journal Impact IF Trend

Related Journals

Popular Journals

CNS Spectrums

The 2019-2020 Journal Impact IF of CNS Spectrums is 3.356, which is just updated in 2020.

CNS Spectrums Impact Factor
Highest IF
3.94
Highest Journal Impact IF

The highest Journal Impact IF of CNS Spectrums is 3.94.

Lowest IF
1.304
Lowest Journal Impact IF

The lowest Journal Impact IF of CNS Spectrums is 1.304.

Total Growth Rate
53.5%
IF Total Growth Rate

The total growth rate of CNS Spectrums IF is 53.5%.

Annual Growth Rate
5.9%
IF Annual Growth Rate

The annual growth rate of CNS Spectrums IF is 5.9%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Psychiatry and Mental Health Q2 153/506

Psychiatry and Mental Health 69%

Neurology (clinical) Q2 148/348

Neurology (clinical) 57%

Journal Impact IF Ranking

· In the Psychiatry and Mental Health research field, the Quartile of CNS Spectrums is Q2. CNS Spectrums has been ranked #153 over 506 related journals in the Psychiatry and Mental Health research category. The ranking percentile of CNS Spectrums is around 69% in the field of Psychiatry and Mental Health.
· In the Neurology (clinical) research field, the Quartile of CNS Spectrums is Q2. CNS Spectrums has been ranked #148 over 348 related journals in the Neurology (clinical) research category. The ranking percentile of CNS Spectrums is around 57% in the field of Neurology (clinical).

CNS Spectrums Impact Factor 2020-2021 Prediction

CNS Spectrums Impact Factor Predition System

CNS Spectrums Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
2780
Total Citations
56505

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 3.356
2018-2019 3.94
2017-2018 3.504
2016-2017 3.589
2015-2016 3.582
2014-2015 2.71
2013-2014 1.304
2012-2013 1.727
2011-2012 2.186
Journal Impact IF History

· The 2019-2020 Journal Impact IF of CNS Spectrums is 3.356
· The 2018-2019 Journal Impact IF of CNS Spectrums is 3.94
· The 2017-2018 Journal Impact IF of CNS Spectrums is 3.504
· The 2016-2017 Journal Impact IF of CNS Spectrums is 3.589
· The 2015-2016 Journal Impact IF of CNS Spectrums is 3.582
· The 2014-2015 Journal Impact IF of CNS Spectrums is 2.71
· The 2013-2014 Journal Impact IF of CNS Spectrums is 1.304
· The 2012-2013 Journal Impact IF of CNS Spectrums is 1.727
· The 2011-2012 Journal Impact IF of CNS Spectrums is 2.186

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1994 0 2
1995 0 5
1996 17 15
1997 79 47
1998 111 124
1999 120 280
2000 115 339
2001 99 307
2002 95 377
2003 123 528
2004 146 671
2005 162 1072
2006 148 1759
2007 175 2420
2008 197 2875
2009 158 3361
2010 90 3857
2011 30 3957
2012 24 4049
2013 52 3933
2014 71 3963
2015 73 3923
2016 59 3494
2017 107 3679
2018 95 2935
2019 149 3571
2020 283 4530
2021 2 432
Publications Cites Dataset

· The CNS Spectrums has published 0 reports and received 2 citations in 1994.
· The CNS Spectrums has published 0 reports and received 5 citations in 1995.
· The CNS Spectrums has published 17 reports and received 15 citations in 1996.
· The CNS Spectrums has published 79 reports and received 47 citations in 1997.
· The CNS Spectrums has published 111 reports and received 124 citations in 1998.
· The CNS Spectrums has published 120 reports and received 280 citations in 1999.
· The CNS Spectrums has published 115 reports and received 339 citations in 2000.
· The CNS Spectrums has published 99 reports and received 307 citations in 2001.
· The CNS Spectrums has published 95 reports and received 377 citations in 2002.
· The CNS Spectrums has published 123 reports and received 528 citations in 2003.
· The CNS Spectrums has published 146 reports and received 671 citations in 2004.
· The CNS Spectrums has published 162 reports and received 1072 citations in 2005.
· The CNS Spectrums has published 148 reports and received 1759 citations in 2006.
· The CNS Spectrums has published 175 reports and received 2420 citations in 2007.
· The CNS Spectrums has published 197 reports and received 2875 citations in 2008.
· The CNS Spectrums has published 158 reports and received 3361 citations in 2009.
· The CNS Spectrums has published 90 reports and received 3857 citations in 2010.
· The CNS Spectrums has published 30 reports and received 3957 citations in 2011.
· The CNS Spectrums has published 24 reports and received 4049 citations in 2012.
· The CNS Spectrums has published 52 reports and received 3933 citations in 2013.
· The CNS Spectrums has published 71 reports and received 3963 citations in 2014.
· The CNS Spectrums has published 73 reports and received 3923 citations in 2015.
· The CNS Spectrums has published 59 reports and received 3494 citations in 2016.
· The CNS Spectrums has published 107 reports and received 3679 citations in 2017.
· The CNS Spectrums has published 95 reports and received 2935 citations in 2018.
· The CNS Spectrums has published 149 reports and received 3571 citations in 2019.
· The CNS Spectrums has published 283 reports and received 4530 citations in 2020.
· The CNS Spectrums has published 2 reports and received 432 citations in 2021.
· The total publications of CNS Spectrums is 2780.
· The total citations of CNS Spectrums is 56505.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

CNS Spectrums | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The CNS Spectrums Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the CNS Spectrums during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of CNS Spectrums.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

CNS Spectrums
Journal Profile

About

CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics, and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives, and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies, and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry. None

Highly Cited Keywords

ISSN
1092-8529
ISSN

The ISSN of CNS Spectrums is 1092-8529 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
2165-6509
ISSN (Online)

The ISSN (Online) of CNS Spectrums is 2165-6509 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Cambridge University Press
Publisher

CNS Spectrums is published by Cambridge University Press .

Publication Frequency
Monthly
Publication Frequency

CNS Spectrums publishes reports Monthly .

Coverage
1996 - Present
Coverage

The Publication History of CNS Spectrums covers 1996 - Present .

Open Access
NO
Open Access

CNS Spectrums is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to CNS Spectrums. CNS Spectrums is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

Language
English
Language

The language of CNS Spectrums is English .

Country/Region
United Kingdom
Country/Region

The publisher of CNS Spectrums is Cambridge University Press , which locates in United Kingdom .

Selected Articles

Full Title Authors
Full Title Authors
Examining the validity of the ADHD concept in adults and older adults Brandy L. Callahan · André Plamondon · André Plamondon
119 Refraction Focus Hallucination: The Role of Increased Excitation at Thalamus in Complex Visual Hallucination Chunhui Yang · Jasir T. Nayati · Khurram Janjua · Asma Ahmed · Angela Rekhi · Alan R. Hirsch · Alan R. Hirsch
135 Use of Pimavanserin in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) James Norton · Doral Fredericks · Kathy Chi-Burris · Randy Owen · Randy Owen
127 Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia Donna S. Cox · Micha Levi · Laura Rabinovich-Guilatt · David Truong · David Stamler · David Stamler
136 CerefolinNAC Therapy-Induced Dizziness Jasir T. Nayati · Alan R. Hirsch · Alan R. Hirsch
122 Use of Pimavanserin in Patients With Parkinsons Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment Daniel Weintraub · James Norton · Bruce Coate · Candace Andersson · Doral Fredericks · Clive Ballard · Clive Ballard
182 Unintentional Overdose on Long-Acting Injectable Risperidone Saira Pasha · Shirin Schilling · Shirin Schilling
197 Guanfacine and Impulsivity – Review of Literature William Donovan Vargas · Nevena V. Radonjic · Nevena V. Radonjic
112 Healthcare Utilization and Costs for Patients With Tardive Dyskinesia Benjamin Carroll · Paul Juneau · Debra E. Irwin · Debra E. Irwin
163 Treatment of Odor-Induced Anxiogenesis With Odor-Induced Anxiolysis Muktiben M. Patel · Nigam D. Patel · Angela Rekhi · Alan R. Hirsch · Alan R. Hirsch
116 Retrospective Analysis of Clozapine Augmentation in Treatment-Resistant Schizophrenia in an Outpatient Setting Charles Odom · Frozan Walyzada · Pankaj Manocha · Monika Gashi · Ashaki Martin · Raminder Cheema · Wen Gu · Ketki Shah · Panagiota Korenis · Panagiota Korenis
118 Demographics and Real World Healthcare Cost and Utilization for Patients With Probable Tardive Dyskinesia Michael Polson · Chuck Yonan · Ted Williams · Ted Williams
161 The NeuroStar Outcomes Registry Miriam Mina · David G. Brock · W. Scott West · Todd Hutton · Kenneth P. Pages · Timothy J. Kane · Timothy J. Kane
160 Optimizing TMS Treatment for Depression - The 19 Minute Dash™ Protocol Miriam Mina · David G. Brock · Alvaro Pascual-Leone · Mark A. Demitrak · Mark A. Demitrak
120 Fragile X Syndrome Sharing Similar Neural Network Abnormalities as ADHD Chunhui Yang · Carolyn Beebe Smith · Guoqiang Xing · Sandeep Gaonkar · Sandeep Gaonkar
187 Buprenorphine/Naloxone (Suboxone and Bunavail)-Induced Glycolimia, an Indication of Undermedication? Stefany Kress · Alan R. Hirsch · Alan R. Hirsch
186 Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Schizophrenia Stanley N. Caroff · Fan Mu · Rajeev Ayyagari · Traci Schilling · Victor Abler · Benjamin Carroll · Benjamin Carroll
198 Who Am I: Delusion of Misidentification of Self Yara W. Moustafa · Alican Dalkilic · Alican Dalkilic
177 Management of Treatment-Resistant Schizophrenia With Clozapine Augmentation Emelina Arocha · Juan D. Oms · Luxhman Gunaseelan · Golbon Foroughi · Syed Rizvi · Syed Rizvi
179 Dasotraline in Children With Attention Deficit Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Study Robert S. Goldman · Lenard A. Adler · Thomas J. Spencer · Robert L. Findling · Seth C. Hopkins · Kenneth K. Koblan · Kaushik Sarma · Jay Hsu · Antony Loebel · Antony Loebel
128 Effect of DR/ER-MPH on Early Morning and Late Afternoon/Evening Functioning in Children With ADHD: Analysis of PREMB-R Items From a Phase 3 Trial Steven R. Pliszka · Valerie Arnold · Andrea Marraffino · Norberto J. DeSousa · Bev Incledon · F. Randy Sallee · Timothy E. Wilens · Jeffrey H. Newcorn · Jeffrey H. Newcorn
144 A Clinical Practice Assessment In Tardive Dyskinesia: Are Physicians Up-to-Date? Jovana Lubarda · Stacey Hughes · Christoph U. Correll · Christoph U. Correll
137 Menstrual Synchrony of Burning Mouth Syndrome Jasir T. Nayati · Alan R. Hirsch · Alan R. Hirsch
141 The Effects of Valbenazine on Tardive Dyskinesia: Subgroup Analyses of 3 Randomized, Double-Blind, Placebo-Controlled Trials Jonathan M. Meyer · Gary Remington · Ali Norbash · Joshua Burke · Scott Siegert · Grace S. Liang · Grace S. Liang
142 The Burden of Tardive Dyskinesia Secondary to Antipsychotic Medication Use Among Patients With Mental Disorders Joseph P. McEvoy · Tyson Park · Traci Schilling · Emi Terasawa · Rajeev Ayyagari · Benjamin Carroll · Benjamin Carroll
143 Effect of Tardive Dyskinesia on Quality of Life: Patient-Reported Symptom Severity Is Associated With Deficits in Physical, Mental, and Social Functioning Joseph P. McEvoy · Benjamin Carroll · Sanjay Gandhi · Avery A. Rizio · Stephen Maher · Mark Kosinski · Jakob B. Bjorner · Jakob B. Bjorner
192 Multi-Watt Near Infrared Phototherapy is an Effective Treatment for Depression Theodore Henderson · Larry Dwayne Morries · Larry Dwayne Morries
185 Second Generation Antipsychotics and Catatonia: A Literature Review Ryan Slauer · Mina Boazak · Michael Lowley · Jeffrey Lawrence · Zachary Hudson · David Goldsmith · Robert O. Cotes · Robert O. Cotes
175 Burning Mouth Syndrome Equivalent to Restless Leg Syndrome Priya Batta · Sarosh Majeed · Davinder Dhillon · Alan R. Hirsch · Alan R. Hirsch
146 Effect of Heroin Use on Changes of Brain Functions as Measured by fMRI, a Systematic Review Jungjin Kim · Ayman Fareed · Bethany Ketchen · Woo Jin Kwak · Danzhao Wang · Hilaire Shongo-Hiango · Karen Drexler · Karen Drexler
132 Effects of Valbenazine on Depression and Suicidality in Adults With Tardive Dyskinesia: Pooled Results of 3 Double-Blind, Placebo-Controlled Trials Gary Remington · Dao Thai-Cuarto · Joshua Burke · Scott Siegert · Grace S. Liang · Grace S. Liang
129 Effect of DR/ER-MPH on Caregiver-Reported ADHD Symptom Improvement in Children With ADHD and Caregiver Strain: Results From a Phase 3 Trial Steven R. Pliszka · Valerie Arnold · Andrea Marraffino · Norberto J. DeSousa · Bev Incledon · F. Randy Sallee · Timothy E. Wilens · Jeffrey H. Newcorn · Jeffrey H. Newcorn
133 Cognitive Impairment Following Overdose on Lamotrigine Geetha Chandrashekar · David Ash · Garima Singh · Garima Singh
150 Estimation of an MCID for AIMS Total Score Change in Tardive Dyskinesia Martha Sajatovic · Andrew J. Cutler · Khodayar Farahmand · Joshua Burke · Scott Siegert · Grace S. Liang · Grace S. Liang
Pharmacotherapy of schizophrenia: toward a metabolomic-based approach Haythum Tayeb · Hussam A. S. Murad · Misbahuddin M Rafeeq · Frank I. Tarazi · Frank I. Tarazi
Initial validation of a Trans-diagnostic Compulsivity Questionnaire: The Cambridge-Chicago Compulsivity Trait Scale Samuel R. Chamberlain · Jon E. Grant · Jon E. Grant
Snack food as a modulator of human resting-state functional connectivity Andrea Mendez-Torrijos · Silke Kreitz · Claudiu Ivan · Laura Konerth · Julie Rösch · Monika Pischetsrieder · Gunther H. Moll · Oliver Kratz · Arnd Dörfler · Stefanie Horndasch · Andreas Hess · Andreas Hess
Costs and benefits of neuroimaging research in obsessive-compulsive disorder: time to take stock Jon E. Grant · Samuel R. Chamberlain · Samuel R. Chamberlain
Political terrorism and affective polarization inblackandredterrorists in Italy during the years 1968–1988 Matteo Pacini · Icro Maremmani · Icro Maremmani
Converting oral to long-acting injectable antipsychotics: a guide for the perplexed– CORRIGENDUM Jonathan M. Meyer · Jonathan M. Meyer
Cognitive remediation in large systems of psychiatric care Alice Medalia · Alice M. Saperstein · Matthew D. Erlich · Lloyd I. Sederer · Lloyd I. Sederer
The history and scope of neuropsychiatry Michael R. Trimble · Michael R. Trimble
Additional occupational therapy considerations for functional neurological disorders: a potential role for sensory processing Jessica Ranford · David L. Perez · Julie MacLean · Julie MacLean
Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD) Pratap Chokka · Joanna Bougie · Emmanouil Rampakakis · Jean Proulx · Jean Proulx
The neurological examination adapted for neuropsychiatry Sheldon Benjamin · Margo D. Lauterbach · Margo D. Lauterbach
Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder Andrea E. Cavanna · Andrea E. Cavanna
Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual Giacomo Grassi · Martijn Figee · Pieter Ooms · Lorenzo Righi · Takashi Nakamae · Stefano Pallanti · Rick Schuurman · Damiaan Denys · Damiaan Denys
Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia Joep H. Schoemaker · A.J.J.M. Vingerhoets · Robin Emsley · Robin Emsley
151 Improving the Systematic Use of Pharmacogenetic Testing for Depression Prescribing Lauren Thomann Hughes · Lauren Thomann Hughes
107 Using Brief Motivational Interviewing to Increase Healthy Lifestyle Habits in Overweight and Obese Adults in a Rural Family Practice Setting Amanda McNulty · Amanda McNulty
183 AXONA (Caprylidene): Medical Food Therapy For Alzheimers Disease Shanila Shagufta · Venkatesh Sreeram · Faisal Kagadkar · Faisal Kagadkar
170 Prospective Evaluation of the Economic Utility of Combinatorial Pharmacogenomics in Generalized Anxiety Disorder and Major Depressive Disorder Nathan Roe · Catherine Passariello · Lisa C. Brown · James Li · Michael Jablonski · Bryan M. Dechairo · Bryan M. Dechairo
195 Current Use and Trends in the Management of Tardive Dyskinesia: Role of VMAT2 Inhibitors Venkatesh Sreeram · Shanila Shagufta · Faisal Kagadkar · Mustafa Qureshi · Mustafa Qureshi
148 Visual Snow Defeats Guardians of the Galaxy Volume 2: Unremitting Pixelation Despite Three-Dimentional Stereoscopic Film Kanchan S Prashar · Abraham M Titus · Vishal Kinkhabwala · Alan R. Hirsch · Alan R. Hirsch
156 Improvement in Disease Severity in Patients With Treatment-Resistant Depression Following Treatment With Intranasal Esketamine Abigail Nash · May Shawi · Jaskaran Singh · Ella J. Daly · Kimberly Copper · Pilar Lim · Rosanne Lane · Jagadish Gogate · Allitia DiBernardo · David Hough · Larry Alphs · Larry Alphs
176 The Influence of Chronic Stress on the Development of Psychiatric Conditions Rhaisa Dumenigo · Juan D. Oms · Luxhman Gunaseelan · Golbon Foroughi · Syed Rizvi · Syed Rizvi
158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study Karen E. Anderson · Mat D. Davis · Stewart A. Factor · Robert A. Hauser · L. Fredrik Jarskog · Joohi Jimenez-Shahed · Rajeev Kumar · Stanislaw Ochudlo · William G. Ondo · Hubert H. Fernandez · Hubert H. Fernandez
125 Short Duration Monoballismus Davinder Dhillon · Priya Batta · Alan R. Hirsch · Alan R. Hirsch
193 A New Syndrome: Phantogeusia-Induced Phantosmia Umar Ahmad · Alan R. Hirsch · Alan R. Hirsch
124 Epochs of Anosmia and Ageusia in Multiple Sclerosis: Chemosensory Uhthoffs Phenomenon Davinder Dhillon · Jasir T. Nayati · Priya Batta · Alan R. Hirsch · Alan R. Hirsch
149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study Karen E. Anderson · Mat D. Davis · Stewart A. Factor · Robert A. Hauser · L. Fredrik Jarskog · Joohi Jimenez-Shahed · Rajeev Kumar · Frcpc · Stanislaw Ochudlo · William G. Ondo · Hubert H. Fernandez · Hubert H. Fernandez
134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies Hubert H. Fernandez · Mat D. Davis · Stewart A. Factor · Robert A. Hauser · L. Fredrik Jarskog · Joohi Jimenez-Shahed · Rajeev Kumar · Stanislaw Ochudlo · William G. Ondo · Karen E. Anderson · Karen E. Anderson
111 A Novel Dual-Channel Deep Transcranial Magnetic Stimulator for Major Depressive Disorder Eiran Vadim Harel · Dikla Shmuel · Daniel Antler · Dana Katz · Elina Pushkarski · Ezekiel Ais · Anna Schvartz · Aron Tendler · Yiftach Roth · Abraham Zangen · Yechiel Levkovitz · Yechiel Levkovitz
Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough Stephen M. Stahl · Stephen M. Stahl
108 Lurasidone in Children and Adolescents With Bipolar Depression Presenting With Mixed Features Cynthia Siu · Andrei Pikalov · Michael Tocco · Antony Loebel · Antony Loebel
139 Burning Mouth Syndrome After Hemicolectomy and Hyperalimentation Jasmine M. Campbell · Jasir T. Nayati · Alan R. Hirsch · Alan R. Hirsch
Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder Verinder Sharma · Minakshi Doobay · Minakshi Doobay
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period Peter J. Weiden · Yangchun Du · Chih-Chin Liu · Arielle D. Stanford · Arielle D. Stanford
Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate Stephen M. Stahl · Stephen M. Stahl
Pimavanserin for the treatment of Parkinsons disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed Leslie Citrome · James Norton · Kathy Chi-Burris · George Demos · George Demos
130 Consistent Efficacy of DR/ER-MPH on Early Morning Functioning in Children With ADHD: Analysis of BSFQ Item Ratings From a Pivotal Phase 3 Trial Timothy E. Wilens · Steven R. Pliszka · Valerie Arnold · Andrea Marraffino · Norberto J. DeSousa · Bev Incledon · F. Randy Sallee · Jeffrey H. Newcorn · Jeffrey H. Newcorn
Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor Le Xiao · Christoph U. Correll · Lei Feng · Yu-Tao Xiang · Yuan Feng · Changqing Hu · Rena Li · Gang Wang · Gang Wang
Mixed-up about how to diagnose and treat mixed features in major depressive episodes – CORRIGENDUM Stephen M. Stahl · Stephen M. Stahl
Psychiatric, behavioral, and cognitive disorders in patients with extracranial cancers Gabriella Pravettoni · Bernardo Dell’Osso · T. Bocci · T. Bocci · Francesca Cortese · Francesca Cortese · Roberta Ferrucci · Roberta Ferrucci · Valentina Lampis · Chiara Rosci · Alberto Priori · Alberto Priori
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia Henry A. Nasrallah · Ralph Aquila · Yangchun Du · Arielle D. Stanford · Amy Claxton · Peter J. Weiden · Peter J. Weiden
162 Add-on Filgrastim During Clozapine Rechallenge Unsuccessful in Treating Benign Ethnic Neutropenia Molly Britton · Palanikumar Gunasekar · Vithyalakshmi Selvaraj · Vithyalakshmi Selvaraj
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? Stephen M. Stahl · Stephen M. Stahl
Neuronal underpinnings of cognitive impairment and - improvement in mood disorders Kamilla W. Miskowiak · Cecilia S. Petersen · Cecilia S. Petersen
Dysphagia characteristics in Huntingtons disease patients: insights from the Fiberoptic Endoscopic Evaluation of Swallowing and the Swallowing Disturbances Questionnaire Yael Manor · Yael Oestreicher-Kedem · Alona Gad · Jennifer Zitser · Achinoam Faust-Socher · Dina Shpunt · Stav Naor · Noit Inbar · Meir Kestenbaum · Nir Giladi · Tanya Gurevich · Tanya Gurevich
Odor sensitivity impairment: a behavioral marker of psychological distress? David C. Houghton · Samuel L. Howard · Thomas W. Uhde · Caitlin Paquet · Rodney J. Schlosser · Bernadette M. Cortese · Bernadette M. Cortese
Conducting clinical studies targeting cognition in psychiatry: guiding principles and design Tamsyn E. Van Rheenen · Kathryn E. Lewandowski · Jessica M. Lipschitz · K. E. Burdick · K. E. Burdick
Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs Kellie J. Goodlet · Monika T. Zmarlicka · Alyssa M. Peckham · Alyssa M. Peckham
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study Christoph U. Correll · Lily Shi · Catherine Weiss · Mary Hobart · Anna Eramo · Ruth Duffy · Emmanuelle Weiller · Ross A. Baker · Ross A. Baker
121 Enhancing Emotional Wellness With Smartphone Apps in Early Psychosis Dale D’Mello · Dale D’Mello
Skin picking disorder: prevalence, correlates, and associations with quality of life in a large sample Myrela O. Machado · Cristiano A. Köhler · Brendon Stubbs · Paulo R. Nunes-Neto · Ai Koyanagi · João Quevedo · Jair C. Soares · Thomas Hyphantis · Donatella Marazziti · Michael Maes · Dan J. Stein · André F. Carvalho · André F. Carvalho
145 Improving Management of Mood Disorders Through an Online Interactive Patient Case Challenge Jovana Lubarda · Piyali Chatterjee-Shin · Joseph F. Goldberg · Joseph F. Goldberg
181 Triple Trouble: A Rare Case Report of PCDH19, Autism and Epilepsy in a 7-Year-Old Male Child Sailaja Bysani · Jusleen Kendhari · Cale Robert · Cale Robert
100 Reciprocal Relationship Between Olfactory Ability and Olfactory Hallucination Usama Bardan · Stefany Kress · Alan R. Hirsch · Alan R. Hirsch
174 Pseudogout Induced by Vortioxetine Priya Batta · Davinder Dhillon · Alan R. Hirsch · Alan R. Hirsch
104 Valproate-Induced Hyperammonemic Encephalopathy: Case Studies Dan Matthews · Glenda Matthews · Glenda Matthews
178 Gender Differences in Prodromal Symptoms of Dementia Richard Wallis · Sheryl Bishop · Brian Downer · Thomas Méndez · Mukaila A. Raji · Aida Sapp · Aida Sapp
180 Efficacy of Dasotraline in Children With Attention Deficit Hyperactivity Disorder in a Laboratory Classroom Setting Robert S. Goldman · Ann Childress · Sharon B. Wigal · Seth C. Hopkins · Kenneth S. Koblan · Kaushik Sarma · Jay Hsu · Antony Loebel · Antony Loebel
189 Emetophobia: The Specific Phobia of Vomiting: 2 Case Studies With 1-Year Follow-up Sultana Jahan · Sailaja Bysani · Sailaja Bysani
123 Adjunctive Brexpiprazole in Patients With MDD and Symptoms of Anxiety: Results From Post-Hoc Analyses of Three Placebo-Controlled Studies Emmanuelle Weiller · Anna-Greta Nylander · Catherine Weiss · Peter Zhang · Mary Hobart · Mary Hobart
117 RE-KINECT: Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Interim Baseline Burden of Illness Results Andrew J. Cutler · Stanley N. Caroff · Caroline M. Tanner · William R. Lenderking · Karen Yeomans · Huda Shalhoub · Véronique Pagé · Chuck Yonan · Chuck Yonan
157 Treatment-Refractory Mania With Psychosis in Post-Transplant Patient on Tacrolimus: A Case Report Meelie Bordoloi · Garima Singh · Muaid Ithman · Muaid Ithman
199 Cardiac Safety and QTc Intervals With DM/Q Treatment for Pseudobulbar Affect: A Review of Clinical Trial Data Jay W. Mason · Emmanuelle Hugentobler · Andrea E. Formella · Laura E. Pope · Laura E. Pope
109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis Celso Arango · Daisy Ng-Mak · Elaine Finn · Aidan Byrne · Krithika Rajagopalan · Antony Loebel · Antony Loebel
188 Buspirone-Induced Somnambulism Sulekho Egal · Alan R. Hirsch · Alan R. Hirsch
110 Increased Intracranial Pressure induced Mal de Debarquement Syndrome Angela Rekhi · Alan R. Hirsch · Alan R. Hirsch
138 Gait Ignition Failure Syndrome Secondary to Spinal Stenosis Jasir T. Nayati · Angela Rekhi · Alan R. Hirsch · Alan R. Hirsch
113 Dasotraline for the Treatment of Moderate to Severe Binge Eating Disorder in Adults: Results From a Randomized, Double-Blind, Placebo-Controlled Study Bradford Navia · James I. Hudson · Susan L. McElroy · Anna I. Guerdjikova · Ling Deng · Kaushik Sarma · Seth C. Hopkins · Kenneth S. Koblan · Antony Loebel · Robert S. Goldman · Robert S. Goldman
191 Multi-Watt Near Infrared Phototherapy as a Treatment for Traumatic Brain Injury Theodore Henderson · Larry Dwayne Morries · Larry Dwayne Morries
Neuronal traffic signals in tardive dyskinesia: not enoughstopin the motor striatum Stephen M. Stahl · Stephen M. Stahl
New medications for treatment-resistant depression: a brief review of recent developments Michael E. Thase · Michael E. Thase
A review of the neurobiology of obesity and the available pharmacotherapies Mehala Subramaniapillai · Roger S. McIntyre · Roger S. McIntyre
Converting oral to long-acting injectable antipsychotics: a guide for the perplexed Jonathan M. Meyer · Jonathan M. Meyer
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to lessgoand morestopfrom the motor striatum for robust therapeutic effects Stephen M. Stahl · Stephen M. Stahl
Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high risk for psychosis: a pilot study Maiara Zeni-Graiff · Adiel C. Rios · Pawan Kumar Maurya · Lucas B. Rizzo · Sumit Sethi · Ana S. Yamagata · Rodrigo B. Mansur · Pedro Mario Pan · Elson Asevedo · Graccielle R. Cunha · André Zugman · Rodrigo Affonseca Bressan · Ary Gadelha · Elisa Brietzke · Elisa Brietzke
Availability of dopamine transporters and auditory P300 abnormalities in adults with attention-deficit hyperactivity disorder: preliminary results Ching-Lin Chu · I. Hui Lee · Mei Hung Chi · Kao Chin Chen · Po See Chen · Wei Jen Yao · Nan-Tsing Chiu · Yen Kuang Yang · Yen Kuang Yang
Occupational therapy for functional neurological disorders: a scoping review and agenda for research Paula Gardiner · Lindsey MacGregor · Alan Carson · Jon Stone · Jon Stone
Group independent component analysis reveals alternation of right executive control network in Internet gaming disorder Lingxiao Wang · Yifen Zhang · Xiao Lin · Hongli Zhou · Xiaoxia Du · Guangheng Dong · Guangheng Dong
Neurodegeneration of brain networks in the amyotrophic lateral sclerosis–frontotemporal lobar degeneration (ALS–FTLD) continuum: evidence from MRI and MEG studies Francesca Trojsi · Pierpaolo Sorrentino · Giuseppe Sorrentino · Gioacchino Tedeschi · Gioacchino Tedeschi
Problematic internet use in gamblers: impact on clinical and cognitive measures Samuel R. Chamberlain · Sarah A. Redden · Eric W. Leppink · Jon E. Grant · Jon E. Grant
Psychopathology of terrorists Armando Piccinni · Donatella Marazziti · Antonello Veltri · Antonello Veltri
Pharmacogenetic testing for the guidance of psychiatric treatment of a schizoaffective patient with haltlose personality disorder João Gama Marques · João Gama Marques
Psychopharmacological options for adult patients with anorexia nervosa: the patients and carers perspectives integrated by the spectrum model Mario Miniati · Donatella Marazziti · Donatella Marazziti
Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes Stephen M. Stahl · Stephen M. Stahl
Addiction to death Marc Reisinger · Marc Reisinger
Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties? Patrick M. Lemoine · Stephen M. Stahl · Stephen M. Stahl
Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration Massimiliano Buoli · Massimiliano Buoli · Chiara Rovera · Sara Pozzoli · Alessio Fiorentini · Alessio Fiorentini · Laura Cremaschi · Alice Caldiroli · A. Carlo Altamura · A. Carlo Altamura · A. Carlo Altamura
Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine Claudio N. Soares · Min Zhang · Matthieu Boucher · Matthieu Boucher
Evolution of circuits regulating pleasure and happiness with the habenula in control Anton J. M. Loonen · Svetlana A. Ivanova · Svetlana A. Ivanova
How to fight terrorism? Political and strategic aspects Erich Vad · Erich Vad
Efficacy of vortioxetine in working patients with generalized anxiety disorder Michael Cronquist Christensen · Henrik Loft · Ioana Florea · Roger S. McIntyre · Roger S. McIntyre
The international scenario of terrorism Donato Marzano · Donato Marzano
The mind of suicide terrorists Donatella Marazziti · Antonello Veltri · Armando Piccinni · Armando Piccinni
Treating depressive episodes or symptoms in patients with schizophrenia Geeske van Rooijen · Jentien Vermeulen · Henricus G. Ruhé · Lieuwe de Haan · Lieuwe de Haan
Is there enoughinterest in and pleasure inthe concept of depression? The development of the Leuven Affect and Pleasure Scale (LAPS) Koen Demyttenaere · Philippe Mortier · Glenn Kiekens · Ronny Bruffaerts · Ronny Bruffaerts
A neuropsychiatric case report: Klüver–Bucy and Gastaut–Geschwind syndromes in one patient with schizoaffective disorder presenting with brain 99-mTc HMPAO single-photon emission computed tomography showing bilateral discrete decrease of temporal lobes perfusion João Gama Marques · João Gama Marques
Emerging treatments for the behavioral and psychological symptoms of dementia Abhinav Anand · Puneet Khurana · Jasneet Chawla · Neha Sharma · Navneet Khurana · Navneet Khurana
Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder Luisa Prochazkova · Linden Parkes · Andrew Dawson · George J. Youssef · Gabriela M. Ferreira · Valentina Lorenzetti · Rebecca Segrave · Leonardo F. Fontenelle · Murat Yücel · Murat Yücel
Why is terrorism a mans business? Anne Maria Möller-Leimkühler · Anne Maria Möller-Leimkühler
Hyperkinesia in ancient China: perspectives and prescriptions Jia Liu · Lu-ning Wang · Lu-ning Wang
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study Leslie Citrome · Robert Risinger · Andrew J. Cutler · Yangchun Du · Jacqueline Zummo · Henry A. Nasrallah · Bernard L. Silverman · Bernard L. Silverman
A perspective on the editorial by Ken Gillman: Much ado about nothing: monoamine oxidase inhibitors, drug interactions, and dietary tyramine Sue Trupin · Sue Trupin
Clinical characterization of Italian suicide attempters with bipolar disorder Bernardo Dell’Osso · Matteo Vismara · Cristina Dobrea · Laura Cremaschi · Benedetta Grancini · Chiara Arici · B. Benatti · Massimiliano Buoli · Terence A. Ketter · A. Carlo Altamura · A. Carlo Altamura
Beyond the pill: new medication delivery options for ADHD Andrew J. Cutler · Gregory Mattingly · Gregory Mattingly
QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy Anja Friis Elliott · Thibault Johan Mørk · Mikkel Højlund · Thomas Christensen · Rasmus Jeppesen · Nikolaj Juul Madsen · Anne Grethe Viuff · Peter Hjorth · Jens Cosedis Nielsen · Povl Munk-Jørgensen · Povl Munk-Jørgensen
Response to the letters addressingMuch ado about nothing Ken Gillman · Ken Gillman
The forsaking of the clinical EEG by psychiatry: how justified? Nash N. Boutros · Nash N. Boutros
Additional thoughts on teaching and prescribing MAOIs S. Shalom Feinberg · S. Shalom Feinberg
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors Stephen M. Stahl · Stephen M. Stahl
Neuropsychiatric characteristics of antiterrorist operation combatants in the Donbass (Ukraine) Konstantin N. Loganovsky · Natalia A. Zdanevich · Marina V. Gresko · Donatella Marazziti · Tatiana K. Loganovskaja · Tatiana K. Loganovskaja
Brain alterations potentially associated with aggression and terrorism Bernhard Bogerts · Maria Schöne · Stephanie Breitschuh · Stephanie Breitschuh
Clinical management of restless legs syndrome in end-stage renal disease patients Zeyad T. Sahli · Jae Jo · Shaker A. Mousa · Frank I. Tarazi · Frank I. Tarazi
Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study inreal-world,everyday clinical practice Domenico De Berardis · Michele Fornaro · Laura Orsolini · Felice Iasevoli · Carmine Tomasetti · Andrea de Bartolomeis · Nicola Serroni · Ida De Lauretis · Gabriella Girinelli · Monica Mazza · Alessandro Valchera · Alessandro Carano · Federica Vellante · Ilaria Matarazzo · Giampaolo Perna · Giovanni Martinotti · Massimo Di Giannantonio · Massimo Di Giannantonio
Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data Salvatore Gentile · Maria Luigia Fusco · Maria Luigia Fusco
What is the role of conventional antidepressants in the treatment of major depressive episodes with Mixed Features Specifier Gianni L. Faedda · Ciro Marangoni · Ciro Marangoni
A biopsychosocial evaluation of the risk for suicide in schizophrenia Nuwan C. Hettige · Ali Bani-Fatemi · Isaac Sakinofsky · Vincenzo De Luca · Vincenzo De Luca
Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder Michael E. Thase · Carl Gommoll · Changzheng Chen · Kenneth Kramer · Arif O. Khan · Suresh Durgam · Suresh Durgam
The surprising blindness in modern psychiatry: do guidelines really guide? Pedro Antônio Schmidt do Prado-Lima · Pedro Antônio Schmidt do Prado-Lima
Schizo-obsessive spectrum disorders: an update Estêvão Scotti-Muzzi · Osvaldo Luis Saide · Osvaldo Luis Saide
Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity Bernardo Dell’Osso · Cristina Dobrea · Laura Cremaschi · Massimiliano Buoli · Shefali Miller · Terence A. Ketter · A. Carlo Altamura · A. Carlo Altamura
Deep brain stimulation for bipolar disorder-review and outlook Sabrina M. Gippert · Christina Switala · Bettina H. Bewernick · Sarah Kayser · Alena Bräuer · Volker A. Coenen · Thomas E. Schlaepfer · Thomas E. Schlaepfer
Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis Jordi Espadaler · Miquel Tuson · Jose Miguel Lopez-Ibor · Franciso Lopez-Ibor · María Inés López‐Ibor · María Inés López‐Ibor
Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder Paul Hodgkins · Andrew Lloyd · M. Haim Erder · Juliana Setyawan · Margaret Weiss · Rahul Sasané · Beenish Nafees · Beenish Nafees
Treatment recommendations for DSM-5-defined mixed features Joshua D. Rosenblat · Roger S. McIntyre · Roger S. McIntyre
Treatment of mixed features in bipolar disorder Joshua D. Rosenblat · Roger S. McIntyre · Roger S. McIntyre
ADHD symptoms in non-treatment seeking young adults: relationship with other forms of impulsivity Samuel R. Chamberlain · Konstantinos Ioannidis · Eric W. Leppink · Faiza Niaz · Sarah A. Redden · Jon E. Grant · Jon E. Grant
The medial forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder Volker A. Coenen · Thomas E. Schlaepfer · Peter Goll · Peter C. Reinacher · Ulrich Voderholzer · Ludger Tebartz van Elst · Horst Urbach · Tobias Freyer · Tobias Freyer
A systematic review of the heritability of specific psychopathic traits using Hares two-factor model of psychopathy Sapna Dhanani · Veena Kumari · Basant K. Puri · Ian H. Treasaden · Susan Young · Piyal Sen · Piyal Sen
Does treating hearing loss prevent or slow the progress of dementia? Hearing is not all in the ears, but whos listening? Stephen M. Stahl · Stephen M. Stahl
Continuous circular cycling as a predictor of treatment response in bipolar disorders: a comprehensive review of the current literature Antonio Tundo · Paola Cavalieri · Paola Cavalieri
Pharmacological treatment of mixed states Alessandro Cuomo · Viktoriya L Nikolova · Nefize Yalin · Danilo Arnone · Andrea Fagiolini · Allan H. Young · Allan H. Young
What leads to high antipsychotic dosing in forensic patients with schizophrenia Branimir Margetić · Branka Aukst Margetić · Dragutin Ivanec · Tija Žarković Palijan · Tija Žarković Palijan
Mixed features in major depressive disorder: diagnoses and treatments Trisha Suppes · Michael J. Ostacher · Michael J. Ostacher
Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study Andrew J. Cutler · Suresh Durgam · Yao Wang · Raffaele Migliore · Kaifeng Lu · István Laszlovszky · György Németh · György Németh
Between a rock-a-bye and a hard place: mood disorders during the peripartum period Michael Thomson · Verinder Sharma · Verinder Sharma
Dysphoric mania, mixed states, and mania with mixed features specifier: are we mixing things up? Susan L. McElroy · Paul E. Keck · Paul E. Keck
Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older George G. Nomikos · Dapo Tomori · Wei Zhong · John Affinito · William Palo · William Palo
Exclusion of overlapping symptoms in DSM-5 mixed features specifier: heuristic diagnostic and treatment implications Gin S. Malhi · Yulisha Byrow · Tim Outhred · Kristina Fritz · Kristina Fritz
Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM Joseph F. Goldberg · Daisy Ng-Mak · Cynthia Siu · Chien-Chia Chuang · Krithika Rajagopalan · Antony Loebel · Antony Loebel
Do no harm: a paradigm shift in the unchecked use of antidepressants Debbi A. Morrissette · Debbi A. Morrissette
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia Marco Solmi · Nicola Veronese · Nita Thapa · Silvia Facchini · Brendon Stubbs · Michele Fornaro · André F. Carvalho · Christoph U. Correll · Christoph U. Correll
Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice Stephen M. Stahl · Stephen M. Stahl
Approach to atypical Alzheimers disease and case studies of the major subtypes Bradford C. Dickerson · Scott M. McGinnis · Chenjie Xia · Bruce H. Price · Alireza Atri · Melissa E. Murray · Mario F. Mendez · David A. Wolk · David A. Wolk
Optimization of acute stroke care in the emergency department: a call for better utilization of healthcare resources amid growing shortage of neurologists in the United States Jagannadha Avasarala · Keith Wesley · Keith Wesley
Cognitive dysfunction in body dysmorphic disorder: new implications for nosological systems and neurobiological models Kiri Jefferies-Sewell · Samuel R. Chamberlain · Naomi A. Fineberg · Keith R. Laws · Keith R. Laws
Mixed features: evolution of the concept, past and current definitions, and future prospects Alan C. Swann · Alan C. Swann
Guidelines for the recognition and management of mixed depression Stephen M. Stahl · Debbi A. Morrissette · Gianni L. Faedda · Maurizio Fava · Joseph F. Goldberg · Paul E. Keck · Yena Lee · Gin S. Malhi · Ciro Marangoni · Susan L. McElroy · Michael J. Ostacher · Joshua D. Rosenblat · Eva Solé · Trisha Suppes · Minoru Takeshima · Michael E. Thase · Eduard Vieta · Allan H. Young · Mark Zimmerman · Roger S. McIntyre · Roger S. McIntyre
Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders Borwin Bandelow · Borwin Bandelow
The dark side of dopaminergic therapies in Parkinsons disease: shedding light on aberrant salience Michele Poletti · Michele Poletti
Mixed-up about how to diagnose and treat mixed features in major depressive episodes Stephen M. Stahl · Stephen M. Stahl
Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis Alan C. Swann · Maurizio Fava · Joyce Tsai · Yongcai Mao · Andrei Pikalov · Antony Loebel · Antony Loebel
Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Bernardo Dell’Osso · B. Benatti · Chiara Arici · Carlotta Palazzo · Carlotta Palazzo · A. Carlo Altamura · A. Carlo Altamura · Eric Hollander · Naomi A. Fineberg · Dan J. Stein · Humberto Nicolini · Nuria Lanzagorta · Donatella Marazziti · Stefano Pallanti · Michael Van Ameringen · Christine Lochner · Oğuz Karamustafalıoğlu · Luchezar Hranov · Martijn Figee · Lynne M. Drummond · Carolyn I. Rodriguez · John Grant · Damiaan Denys · José M. Menchón · Joseph Zohar · Joseph Zohar
Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study Joyce Tsai · Michael E. Thase · Yongcai Mao · Daisy Ng-Mak · Andrei Pikalov · Antony Loebel · Antony Loebel
Social and psychological consequences of not crying : Possible associations with psychopathology and therapeutic relevance Dale C. Hesdorffer · A.J.J.M. Vingerhoets · Michael R. Trimble · Michael R. Trimble
Current management: migraine headache Stephen D. Silberstein · Stephen D. Silberstein
Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales Ladislav Volicer · Leslie Citrome · Jan Volavka · Jan Volavka
Clinical and therapeutic role of mentalization in schizophrenia—a review Trisevgeni Dimopoulou · Frank I. Tarazi · Evangelia M. Tsapakis · Evangelia M. Tsapakis
Standardization of MRI data and disability quantification in the post-EPIC era Jagannadha Avasarala · Jagannadha Avasarala
Musical hallucinations: a brief review of functional neuroimaging findings Francesco Bernardini · Luigi Attademo · Karen Blackmon · Orrin Devinsky · Orrin Devinsky
Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review Jonathan M. Meyer · Michael A. Cummings · George Proctor · George Proctor
Posttraumatic stress disorder symptom severity is associated with left hippocampal volume reduction: a meta-analytic study Michael D. Nelson · Alecia M. Tumpap · Alecia M. Tumpap
Treating mixed mania/hypomania: a review and synthesis of the evidence Minoru Takeshima · Minoru Takeshima
Kick-Off Editorial for 2017: CNS Spectrums Is on the Move Stephen M. Stahl · Stephen M. Stahl
Decreased lymphocyte dopamine transporter in romantic lovers Donatella Marazziti · Stefano Baroni · Gino Giannaccini · Armando Piccinni · Federico Mucci · Mario Catena Dell’Osso · Grazia Rutigliano · Gabriele Massimetti · Liliana Dell’Osso · Liliana Dell’Osso
Internet addiction: reappraisal of an increasingly inadequate concept Vladan Starcevic · Elias Aboujaoude · Elias Aboujaoude
Mixed features in bipolar disorder Eva Solé · Marina Garriga · Marc Valentí · Eduard Vieta · Eduard Vieta
Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder Gabriela M. Ferreira · Murat Yücel · Andrew Dawson · Valentina Lorenzetti · Leonardo F. Fontenelle · Leonardo F. Fontenelle
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine Yong Kee Choi · Nika Adham · Béla Kiss · István Gyertyán · Frank I. Tarazi · Frank I. Tarazi
Measures of the DSM–5 mixed-features specifier of major depressive disorder Mark Zimmerman · Mark Zimmerman
Much ado about nothing: monoamine oxidase inhibitors, drug interactions, and dietary tyramine Ken Gillman · Ken Gillman
Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study Christoph U. Correll · Josephine Cucchiaro · Robert Silva · Jay Hsu · Andrei Pikalov · Antony Loebel · Antony Loebel
The clinical inadequacy of the DSM-5 classification of somatic symptom and related disorders. An alternative trans-diagnostic model Fiammetta Cosci · Giovanni A. Fava · Giovanni A. Fava
Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project Roger S. McIntyre · Hanna O. Woldeyohannes · Joanna K. Soczynska · Nadia A. Maruschak · Ida Kim Wium-Andersen · Maj Vinberg · Danielle S. Cha · Yena Lee · Holly X. Xiao · Laura Ashley Gallaugher · Roman M. Dale · Mohammad Alsuwaidan · Rodrigo B. Mansur · David J. Muzina · André F. Carvalho · Jeanette M. Jerrell · Sidney H. Kennedy · Sidney H. Kennedy
Comorbidity between neurological illness and psychiatric disorders Dale C. Hesdorffer · Dale C. Hesdorffer
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results Rachelle S. Doody · Stephen D’Amico · Andrew J. Cutler · Charles S. Davis · Paul Shin · Fred Ledon · Charles Yonan · Joao Siffert · Joao Siffert
Differences in memory function between 5-HT1A receptor genotypes in patients with major depressive disorder Keith Wesnes · Seth C. Hopkins · Helen Brooker · Kenneth S. Koblan · Kenneth S. Koblan
Gender and cultural issues in psychiatric nosological classification systems Tanya van de Water · Sharain Suliman · Soraya Seedat · Soraya Seedat
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice Deepti Anbarasan · Gabriel H. Campion · Paul Campion · Jonathan Howard · Jonathan Howard
Expanding the definition of addiction: DSM-5 vs. ICD-11 Jon E. Grant · Samuel R. Chamberlain · Samuel R. Chamberlain
Apathy in patients with Parkinsons disease following deep brain stimulation of the subthalamic nucleus Isabel Hindle Fisher · Hardev Pall · Rosalind Mitchell · Jamilla Kausar · Andrea E. Cavanna · Andrea E. Cavanna
Psychiatry and terrorism: exploring the unacceptable Donatella Marazziti · Donatella Marazziti
Relationship between olfactory function and social cognition in euthymic bipolar patients Guillermo Lahera · Salvador Ruiz-Murugarren · Alberto Fernández-Liria · Jerónimo Saiz-Ruiz · Benjamin Buck · David L. Penn · David L. Penn
Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function Elena Dale · Alan L. Pehrson · Theepica Jeyarajah · Yan Li · Steven C. Leiser · Gennady Smagin · Christina Kurre Olsen · Connie Sanchez · Connie Sanchez
Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission Alan L. Pehrson · Theepica Jeyarajah · Connie Sanchez · Connie Sanchez
The impact of periventricular white matter lesions in patients with bipolar disorder type I Gianluca Serafini · Maurizio Pompili · Marco Innamorati · Nicoletta Girardi · Leonardo Strusi · Mario Amore · Leo Sher · Xenia Gonda · Zoltan Rihmer · Paolo Girardi · Paolo Girardi
Patient-centered assessment of cognitive symptoms of depression Sheri Fehnel · Barbara H. Forsyth · Dana B. DiBenedetti · Natalya Danchenko · Clément François · Thomas Brevig · Thomas Brevig
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish Lewis A. Opler · Mark Opler · Amy F.T. Arnsten · Amy F.T. Arnsten
Dissociable brain correlates for depression, anxiety, dissociation, and somatization in depersonalization-derealization disorder Erwin Lemche · Simon Surguladze · Michael Brammer · Mary L. Phillips · Mauricio Sierra · Anthony S. David · Steven Williams · Vincent Giampietro · Vincent Giampietro
Hypoactive Sexual Desire Disorder: Separating Fact from Fiction Anita H. Clayton · Dennis H. Kim · Dennis H. Kim
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis Paula L. Jacobsen · Atul R. Mahableshwarkar · William Palo · Yinzhong Chen · Marianne Dragheim · Anita H. Clayton · Anita H. Clayton
Separation anxiety disorder from the perspective of DSM-5: clinical investigation among subjects with panic disorder and associations with mood disorders spectrum Camilla Gesi · Marianna Abelli · Alessandra Cardini · Lisa Lari · Luca Di Paolo · Derrick Silove · Stefano Pini · Stefano Pini
Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital Keir Stone-Brown · Mahmood Naji · Alex Francioni · Kyle Myers · Harsh Samarendra · Haseeb Mushtaq-Chaudhry · Stephen Heslop · Samrat Sengupta · Callum C. Ross · Fintan Larkin · Mrigendra Das · Mrigendra Das
Addictive behaviors and personality traits in adolescents Donato Munno · Marta Saroldi · Elisa Bechon · Sara Sterpone · Giuseppina Zullo · Giuseppina Zullo
Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways Marta Martin-Subero · George M. Anderson · Buranee Kanchanatawan · Michael Berk · Michael Maes · Michael Maes
Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia Steven G. Potkin · Dragana Bugarski-Kirola · Chris Edgar · Sherif Soliman · Stephanie Le Scouiller · Jelena Kunovac · Eugenio Miguel Velasco · George Garibaldi · George Garibaldi
Mechanism of action of brexpiprazole: comparison with aripiprazole Stephen M. Stahl · Stephen M. Stahl
Mechanism of action of cariprazine Stephen M. Stahl · Stephen M. Stahl
Emerging pharmacological therapies in schizophrenia: whats new, whats different, whats next? Leslie Citrome · Leslie Citrome
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems Gregory Mattingly · Richard H. Anderson · Richard H. Anderson
A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders Roger S. McIntyre · Yena Lee · Rodrigo B. Mansur · Rodrigo B. Mansur
Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia Jonathan M. Meyer · Jonathan M. Meyer
Recognizing and treating pseudobulbar affect William M. Sauvé · William M. Sauvé
Innovation and pragmatism required to reduce seclusion practices John Tully · Leo McSweeney · Katie Lynn Harfield · Cindie Castle · Mrigendra Das · Mrigendra Das
Objective predictors of outcome in forensic mental health services - a systematic review Ottilie Sedgwick · Susan Young · Mrigendra Das · Kumari · Kumari
Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review Philip Skoretz · Chin Tang · Chin Tang
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials Marco Solmi · Nicola Veronese · Leonardo Zaninotto · Marc L M van der Loos · Keming Gao · Ayal Schaffer · Catherine Reis · Claus Normann · I. Anghelescu · Christoph U. Correll · Christoph U. Correll
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia Kim E · Correll Cu · Mao L · Starr Hl · Larry Alphs · Larry Alphs
The separation of adult separation anxiety disorder David S. Baldwin · Robert Gordon · Marianna Abelli · Stefano Pini · Stefano Pini
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics Timothy Peters-Strickland · Cathy Zhao · Pamela Perry · Anna Eramo · Phyllis M. Salzman · Robert D. McQuade · Brian R. Johnson · Raymond Sanchez · Raymond Sanchez
ICD and DSM: neuroplasticity and staging are still missing Stefano Pallanti · Stefano Pallanti
Psychosis of epilepsy: a multifaceted neuropsychiatric disorder Andres M. Kanner · Ana Maria Rivas-Grajales · Ana Maria Rivas-Grajales
PTSD treatment in light of DSM-5 and thegolden hoursconcept Lior Carmi · Leah Fostick · Shimon Burshtein · Shlomit Cwikel-Hamzany · Joseph Zohar · Joseph Zohar
Bipolar and related disorders in DSM-5 and ICD-10 Alexander Kaltenboeck · Dietmar Winkler · Siegfried Kasper · Siegfried Kasper
Using neuroscience for naming psychotropic drugs Stephen M. Stahl · Stephen M. Stahl
Are the ICD-10 or DSM-5 diagnostic systems able to define those who will benefit from treatment for depression? Stuart A. Montgomery · Stuart A. Montgomery
Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11 Anna Maria Marras · Naomi A. Fineberg · Stefano Pallanti · Stefano Pallanti
Mechanism of action of suvorexant Stephen M. Stahl · Stephen M. Stahl
Psychotic disorders in DSM-5 and ICD-11 Falko Biedermann · W. Wolfgang Fleischhacker · W. Wolfgang Fleischhacker
The intentional brain--a short history of neuropsychiatry Michael Trimble · Michael Trimble
Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11 Ellen Doernberg · Eric Hollander · Eric Hollander
The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials Roger S. McIntyre · Carl Gommoll · Changzheng Chen · Adam Ruth · Adam Ruth
Nonepileptic seizures: an updated review David L. Perez · W. Curt LaFrance · W. Curt LaFrance
Adult autism spectrum as a transnosographic dimension Liliana Dell’Osso · Riccardo Dalle Luche · Mario Maj · Mario Maj

119 Refraction Focus Hallucination: The Role of Increased Excitation at Thalamus in Complex Visual Hallucination
CNS Spectrums | 2018
Chunhui Yang · Jasir T. Nayati · Khurram Janjua · Asma Ahmed · Angela Rekhi · Alan R. Hirsch · Alan R. Hirsch
135 Use of Pimavanserin in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs)
CNS Spectrums | 2018
James Norton · Doral Fredericks · Kathy Chi-Burris · Randy Owen · Randy Owen
136 CerefolinNAC Therapy-Induced Dizziness
CNS Spectrums | 2018
Jasir T. Nayati · Alan R. Hirsch · Alan R. Hirsch